UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average b	ourden
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response	- /													
1. Name and Address of Reporting Person* Weild IV David			2. Issuer Name and Ticker or Trading Symbol BioSig Technologies, Inc. [BSGM]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner						
(Last) (First) (Middle) C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD				3. Date of Earliest Transaction (Month/Day/Year) 12/28/2021						Officer (giv	e title below)	Oth	er (specify below)		
(Street) WESTPORT, CT 06880				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)	Table I - Non-Derivative Securities Acquire				es Acquirec	ired, Disposed of, or Beneficially Owned						
1.Title of S (Instr. 3)	/			Execution Date, if any (Month/Day/Year)		ode	8) (A	Securities Acq (A) or Disposed (nstr. 3, 4 and 5) (A) or (D)	of (D) Ow Tra	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		d 1	Ownership of Born: Direct (D) O	Nature Findirect eneficial wnership nstr. 4)	
Reminder:								in this f	s who respon	equired to	respond	unless the		ed SEC 14	74 (9-02)
								in this f		equired to	respond	unless the		ed SEC 14	74 (9-02)
1. Title of	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	tion of S	l <mark>s, warr</mark> . Numb	er ative es d (A)	in this f displays uired, Dispo options, cor 6. Date Exer	orm are not rest a currently sed of, or Beneavertible secur reisable and Date	equired to valid OME eficially Ov ities)	o respond 3 control r vned d Amount ying	unless the number.			11. Natur of Indirect Beneficia Ownersh (Instr. 4)
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion o	s, warr . Numb f Deriva ecuritie acquired r Dispo	er ative es d (A)	in this f displays uired, Dispo options, cor 6. Date Exer Expiration I	orm are not rest a currently sed of, or Beneavertible secur reisable and Date	equired to valid OME eficially Overities) 7. Title and of Underly Securities	orespond 3 control r wned ad Amount ying and 4)	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indire Beneficia Ownersh (Instr. 4)
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion o	s, warr Numb f Derivate curities cquired r Dispo f (D) Instr. 3,	er ative es d (A)	in this f displays uired, Dispo options, cor 6. Date Exer Expiration I	sed of, or Bendivertible securicisable and Date //Year)	equired to valid OME eficially Overities) 7. Title and of Underly Securities	o respond 3 control r vned d Amount ying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natu of Indire Benefici Ownersh (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Weild IV David C/O BIOSIG TECHNOLOGIES, INC. 55 GREENS FARMS ROAD WESTPORT, CT 06880	X				

Signatures

/s/ Kenneth L. Londoner, attorney-in-fact	04/25/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.